Repligen (NASDAQ:RGEN) Now Covered by Barclays
Barclays initiated coverage on shares of Repligen (NASDAQ:RGEN – Free Report) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $150.00 price target on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. […]
Barclays initiated coverage on shares of Repligen (NASDAQ:RGEN – Free Report) in a research report sent to investors on Tuesday morning, Marketbeat Ratings reports. The brokerage issued an overweight rating and a $150.00 price target on the biotechnology company’s stock. Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. […]
